Zedira offers its expertise in the field of transglutaminase to be an ally in drug development for a limited number of partners.
Until now, preclinical and clinical development targeting transglutaminase suffers from a lack of potent and selective blockers. Zedira has overcome this limitation.

Partnering with Zedira will provide access to our transglutaminase-specific drug development platform, which is composed of 4 modules:

Zedira Service Compound lirary

Medicinal chemists synthesized more than 1,000 small molecules targeting either TG2 or FXIIIa covering a remarkable physicochemical space. We are confident not only having the most potent drug able molecules in hand, some of them oral available, but also having a unique knowledge about candidate drugs tailor-made for distinct indications on the horizon.
Zedira Service Screening

96-well screening platform for hit finding, lead optimization and profiling.

Besides the identification of new molecules blocking tissue transglutaminase, the platform allows for profiling selectivity against all human transglutaminase iso-enzymes (FXIII, TG1, TG2, TG3, TG4, TG5, TG6, and TG7). In addition, animal derived transglutaminases are available for pre-evaluation of inhibitory activities in animal models.
Zedira Service Cell based assays

Will inhibitors penetrate into cells and will they inhibit the targeted transglutaminase at intracellular conditions?

These questions are addressed by our cell based assays.
Zedira Service Crystallization

Co-crystals from highly purified transglutaminase-inhibitor-conjugates are the prerequisite for x-ray diffraction and consecutive structure analysis.
Understanding the interaction of the inhibitors to the targets on a molecular level allows in silico design of improved transglutaminase inhibitors.

Zedira is a reliable partner complementing the skills of pharmaceutical companies in the transglutaminase sector in order to create extra value and shorten development times.

  • News  

    • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Blog

  • Events  

    • 17th International Celiac Disease Symposium

      08.09.2017 - 10.09.2017
      New Delhi, India

    • NLSDays 2017

      12.09.2017 - 14.09.2017
      Malmö, Sweden

    • BIO-Europe

      06.11.2017 - 08.11.2017
      Berlin, Germany

    • MEDICA

      13.11.2017 - 16.11.2017
      Düsseldorf, Germany

    • Gordon Research Conference on: Transglutaminases in Human Disease Processes

      16.06.2018 - 17.06.2018
      Les Diablerets, Switzerland